期刊
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
卷 7, 期 1, 页码 139-143出版社
WILEY
DOI: 10.1002/acn3.50972
关键词
-
资金
- Biogen (IMSE natalizumab and dimethyl fumarate)
- Genzyme (IMSE teriflunomide and alemtuzumab)
- Novartis (IMSE fingolimod)
- Swedish Research Council
- Swedish Research Council for Health, Working Live and Welfare
- AFA foundation
- Swedish Brain Foundation
- Knut, and the Alice Wallenberg Foundation
- Margaretha af Ugglas Foundation
- EU Horizon 2020 MultipleMS [733161]
- Biogen
- Novartis
- Sanofi
Blood Neurofilament light chain (NfL) has been suggested as a promising biomarker in several neurological conditions. Since blood NfL is the consequence of leaked NfL from the cerebrospinal fluid, differences in individuals' Body Mass Index (BMI) or blood volume (BV) might affect its correlation to other biomarkers and disease outcomes. Here, we investigated the correlation between plasma NfL, BMI, and BV in 662 controls and 2,586 multiple sclerosis cases. We found a significant negative correlation between plasma NfL, BMI/BV in both groups. Our results highlight the potential confounding effect of BMI/BV on associations between blood NfL and disease outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据